Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News
April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

April 22nd 2025

Chronic Hand Eczema Has Significant Impacts on Patients' Lives, Survey Reveals

April 9th 2025

Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD

April 9th 2025

Review Explores Skin Health Risks of US Migrant Populations

April 8th 2025

Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Video Series
View All
August 5th 2024

Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa

August 5th 2024

The Role of Surgery in Hidradenitis Suppurativa

July 29th 2024

Managing Pain in Patients with Hidradenitis Suppurativa

July 29th 2024

Ongoing Research in Hidradenitis Suppurativa

July 22nd 2024

Recent Data on Bimekizumab for Hidradenitis Suppurativa

July 22nd 2024

Biologic Therapies for Hidradenitis Suppurativa

July 15th 2024

The Role of Treatment Guidelines for HS

July 15th 2024

Hidradenitis Suppurativa (HS): Staging Considerations and Unmet Needs

July 8th 2024

The Impact of Hidradenitis Suppurativa on Families

July 8th 2024

Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate

Video Interviews
View All
April 15th 2025

Lebrikizumab Shows Promise in Long-Term Atopic Dermatitis Control: Raj Chovatiya, MD, PhD

March 21st 2025

Using AI as Augmented Intelligence to Improve Rare Dermatologic Skin Diseases

March 18th 2025

Finding Value in Older, Generic Dermatologic Therapies

March 14th 2025

Pediatric Alopecia Areata Treatment With Baricitinib, Combination Therapies, Patient Adherence

March 13th 2025

Atopic Dermatitis Treatment Strategies Using Ruxolitinib, Considering Crucial Role of Skin Microbiome

August 20th 2024

Patient Education, Provider Education, and Overall Final Thoughts

August 13th 2024

Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment

August 13th 2024

The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment

August 7th 2024

Dr Steve Feldman on How Adverse Event Risks Influence Atopic Dermatitis Treatment Selection

August 6th 2024

Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

Continuing Medical Education
View All
May 1st 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
May 1st 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Crystal Aguh, MD, FAAD
March 28th 2025

Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches

Cameron Santoro Crystal Aguh, MD, FAAD
Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Crystal Aguh, MD, FAAD
March 26th 2025

Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora

Cameron Santoro Crystal Aguh, MD, FAAD
Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Elizabeth Jones, MD, FAAD
March 22nd 2025

Strategies for Improving Patient Access to Dermatology Care

Cameron Santoro Elizabeth Jones, MD, FAAD
Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Pediatric AD. | Image Credit: Evgeniya Primavera - stock.adobe.com
March 13th 2025

Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care

Cameron Santoro
Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Inpatient dermatology. | Image Credit: Seventyfour - stock.adobe.com
February 20th 2025

Redesigning Inpatient Dermatology to Address Costs, Improve Access

Cameron Santoro
The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to improve care, reduce costs, and address health equity for patients with skin diseases.
Atopic Dermatitis Itch. | Image Credit: Pormezz - stock.adobe.com
February 11th 2025

AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis

Cameron Santoro
Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.
Hidradenitis suppurativa. | Image Credit: Yurii Kibalnik - stock.adobe.com
January 28th 2025

Improving Hidradenitis Suppurativa Outcomes by Addressing Treatment Gaps

Cameron Santoro
Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among these patients.
Psoriasis. | Image Credit: IIIRusya - stock.adobe.com
January 27th 2025

Psoriasis Treatment Remains Effective, Safe After Switch From Ustekinumab to Biosimilar SB17

Cameron Santoro
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis for up to 52 weeks.
Acne. | Image Credit: frank29052515 - stock.adobe.com
January 22nd 2025

Dermocosmetics as Adjunctive Therapy Reduces Sensitivity and Improves Quality of Life in Acne

Marie Bosslett
Dermocosmetics alongside traditional acne treatments improved skin tolerance and reduced acne severity in patients, particularly those using retinoids, leading to enhanced quality of life.
Eczema. | Image Credit: InfiniteStudio - stock.adobe.com
January 14th 2025

Eczema Incidence Associated With Dietary Calcium Intake

Cameron Santoro
Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women were found to potentially benefit from higher calcium consumption.
Hidradenitis Suppurativa. | Image Credit: Lea - stock.adobe.com
January 12th 2025

Hidradenitis Suppurativa: Advancing Treatment With Biologics

Cameron Santoro
Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.
Health care clinics. | Image Credit: Gorodenkoff - stock.adobe.com
January 11th 2025

Student-Run Clinics Expand Access to Dermatology Care

Cameron Santoro
For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.
Vitiligo. | Image Credit: Liga Cerina - stock.adobe.com
January 9th 2025

Vitiligo Linked to Higher Cardiovascular Disease Risk

Cameron Santoro
Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.
FDA stamp of approval | Image Credit: Olivier Le Moal - stock.adobe.com
December 16th 2024

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

Brooke McCormick
The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.
Collaborating for Cancer Care Equity: Community and Academic Insights
November 21st 2024

Collaborating for Cancer Care Equity: Community and Academic Insights

Maggie L. Shaw
Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.
Book titled hidradenitis suppurativa | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
September 25th 2024

Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients

Brooke McCormick
A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Semaglutide | Image Credit: Corona Borealis - stock.adobe.com
September 24th 2024

Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

Cameron Santoro
Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.
Diversity animation | Image Credit: annaspoka - stock.adobe.com
September 17th 2024

Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color

Brooke McCormick
Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Silhouettes of different skin colors | Image Credit: freshidea - stock.adobe.com
September 17th 2024

Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials

Brooke McCormick
Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
FDA approved stamp | Image Credit: Olivier Le Moal - stock.adobe.com
September 16th 2024

FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis

Brooke McCormick
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Image Credit: Andrew Popov - stock.adobe.com
September 13th 2024

Experts Highlight New Dermatological Treatments, Importance of Clinical Trial Diversity

Brooke McCormick
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and emphasized the importance of clinical trial diversity.
hands of a patient with vitiligo | Image Credit: Rabizo Anatolii - stock.adobe.com
September 5th 2024

Patients With Vitiligo Experience Poorer Quality of Life but Greater Health Care Access, Utilization

Brooke McCormick
Compared with those without vitiligo, patients with vitiligo have higher health care access and utilization but report a lower quality of life.
AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com
August 28th 2024

Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy

Cameron Santoro Brooke McCormick
Kristen Whitney, DO, FAAD, dermatologist within the Allegheny Health Network, discusses advancements in dermoscopy, predicting that emerging technologies and artificial intelligence (AI) will improve dermatologists' efficiency in monitoring and diagnosing skin conditions.
Woman with vitiligo covering face with her hands | Image Credit: Savory - stock.adobe.com
August 19th 2024

Vitiligo, Mental Health Tied to Higher Health Care Utilization and Costs

Brooke McCormick
Patients with vitiligo and psychosocial comorbidities face significantly higher overall health care utilization and costs, although their vitiligo-related expenditures remain similar to those without such comorbidities.
FDA approval | Image Credit: BHM - stock.adobe.com
August 13th 2024

FDA Approves Nemolizumab for Adult Patients With Prurigo Nodularis

Brooke McCormick
The FDA has approved nemolizumab (Nemluvio; Galderma) to treat patients with prurigo nodularis based on successful phase III trials demonstrating significant reductions in itch and sleep disturbances.
Child scratching arm | Image credit: cunaplus - stock.adobe.com
August 12th 2024

Corticosteroids vs Noncorticosteroids in Pediatric Dermatology: Challenges and Considerations

Pearl Steinzor
Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering the specific needs and risks of each child.
A panel of 4 experts on chronic spontaneous urticaria
August 6th 2024

Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

Brian Keegan, MD, PhD Giselle Mosnaim, MD Stanley Goldstein, MD Anitha Shrikhande, MD, MPH
Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.
Guselkumab | Image credit: luchschenF - stock.adobe.com
August 6th 2024

Extended Guselkumab Dosing Every 16 Weeks Proven Effective for Psoriasis Maintenance

Pearl Steinzor
This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.
Dr Steve Feldman: Dupilumab Has Become the "Gold Standard" for Atopic Dermatitis Treatments
August 3rd 2024

Dr Steve Feldman: Dupilumab Has Become the "Gold Standard" for Atopic Dermatitis Treatments

Brooke McCormick
Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, considers dupilumab the "gold standard" for itch control in patients with atopic dermatitis due to its minimal adverse effects.
Dermatologists examine hair loss. | Image Credit: Cienpies Design - stock.adobe.com
August 1st 2024

Research Explores Novel Insights on Pediatric Hair Loss

Cameron Santoro
Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.
12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo